Asthma Sample Clauses
The Asthma clause defines the terms and conditions related to coverage, treatment, or management of asthma within an agreement, typically in insurance or healthcare contexts. It may specify what types of asthma-related treatments, medications, or hospitalizations are covered, outline any exclusions or limitations, and detail the process for claims or pre-authorization. This clause ensures clarity regarding the responsibilities and entitlements of the parties concerning asthma, helping to prevent disputes and manage expectations about coverage or care.
Asthma. The following services related to asthma are covered with $0 Out-of-Pocket Cost when linked to a primary diagnosis of asthma and performed by a Network Provider: • Office visits to a Primary Care Provider for routine management of asthma • Office visits to a Pulmonologist (lung specialist) for consultation and routine management of asthma • Office visits to an Allergist (allergy specialist) for consultation and routine management of asthma • Palliative care conversations (chronic condition treatment preferences) with Primary Care Provider, Pulmonologist, or Allergist • Immunotherapy for allergen sensitization to reduce impact and severity of allergic reactions • Inhaler adjuncts (e.g., spacer) as specified on the formulary and dispensed through our Home Delivery Program • Pulmonary function tests • Asthma education [allergens/triggers, asthma action plan and behavioral modification counseling] • Targeted laboratory tests for the routine management of asthma Please note, if you have complications from asthma and use an urgent care center, emergency department, or have a Hospital stay, services will be subject to standard Out-of-Pocket Costs as outlined in your Schedule of Benefits.
Asthma. Asthma is a chronic, incurable disease which causes many symptoms that make breathing difficult [3]. Around 5% of the Medicare population in the Parkview area is affected by asthma, as well a portion of the population of adults and children. Asthma as a chief health concern was not mentioned in the community or provider surveys, but asthma in the Medicare population appeared as a primary concern in several of the seven counties according to HCI. While the population affected may be small, the disease burden is high due to expensive and potentially life-long costs associated with managing symptoms of asthma. There are several clinical intervention strategies recommended by healthcare professionals to reduce the frequency and severity of symptoms. Table 5: Asthma ▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇▇ Kosciusko LaGrange Noble Wabash ▇▇▇▇▇▇▇ Asthma 5.6% 6% 4.5% 3.6% 5.5% 4.8% 5.5%
Asthma. Implement targeted education and outreach activities to increase awareness of and disseminate resources on childhood asthma management, including management before, during and after a disaster. Grantee will:
a. Develop and submit to DSHS on an approved template an education and outreach plan that identifies measurable objectives, activities for accomplishing objectives, timeframe for completion, and key partners. The plan should also include communication strategies and target audiences. The education and outreach plan must be submitted to DSHS within 30 days of contract execution.
b. Develop and submit to DSHS an evaluation plan using a DSHS-approved template. The evaluation plan must be submitted to DSHS within 45 days of contract execution.
c. Conduct outreach to at least five (5) communities/cities, specifically those severely impacted by Hurricane ▇▇▇▇▇▇ to provide education and resources on childhood asthma management, including management before, during, and after a disaster by May 31, 2020.
d. Conduct outreach to at least five (5) school districts to provide education and resources on childhood asthma management, including management before during and after a disaster by May 31, 2020.
e. Submit monthly progress reports to the DSHS Contract Manager in compliance with the report submission schedule listed in the report template. The report will be provided by DSHS after contract execution.
f. Submit a Final Progress Report Draft to DSHS using approved template. Report will include summary of all items/activities conducted to date; detailed description of progress toward achieving objectives and activities; plans for sustaining activities once funding has ended; and barriers/lessons learned. The Final Progress Report must be submitted to DSHS on June 14, 2020.
Asthma. Since phthalates are well-known endocrine disruptors, a large amount of research focuses on effects on the reproductive system, the thyroid and metabolism (Huang, Kuo, Guo, Liao, & ▇▇▇, 2007; Lyche et al., 2009). We are interested in its influence on respiratory system. Asthma, characterized by recurrent bronchial hyperresponsiveness, is one of most common pulmonary diseases in the ▇▇▇▇▇▇ ▇▇▇▇▇▇. ▇▇ ▇▇▇▇-▇▇▇▇, asthma prevalence was 8.8% among adults. Overall asthma prevalence among adults increased from 2001-2002 (7.1%) to 2013-2014 (9.2%) (CDC). Common clinical symptoms of asthma include coughing, wheezing, shortness of breath and chest tightness. Symptoms are typically exacerbated at night and in the early morning or related to exercise or inspiration of cold air in winter. Airway inflammation, airflow obstruction, and irreversible airway remodeling are believed to be involved in asthma development. The respiratory system of a human contains two lungs, the trachea, the bronchi in the mediastinum, and the bronchial trees (bronchi branches). The trachea and its large proximal branches form a passageway for air exchange between the lung and the external environment (Gilroy, 2013). Asthma primarily targets at the bronchi and its subdivisions and conducting bronchioles. The pathogenesis of asthma can be classified into two categories. One is intrinsic asthma mainly caused by viral infection (e.g., rhinovirus, parainfluenza virus, respiratory syncytial virus), air pollutants, aspirin or other nonsteroidal medication use (Goljan, 2013). The other one is extrinsic asthma which involves a classical inflammation process. Mast cells, IgE antibodies, leukotrienes, chemokines and cytokines participate in the inflammation process and lead to histologic changes, such as thickening of the basement membranes, infiltration of inflammatory cells, hypertrophy of mucous glands, hypertrophy of smooth muscle cells and hyperplasia (Kumar, Abbas, & Aster, 2012). Narrowing of the bronchi causes expiratory wheezing in asthma, and the air trapping in distal bronchioles leads to the increased anteroposterior thoracic diameter, especially in long-term untreated asthma patients. Although the mechanisms have not yet been elucidated, there are several encouraging laboratory research findings pertaining to the cellular mechanisms through which phthalates may influence inflammation and allergic response. For example, the production of pro-inflammatory chemokines and cytokines in human mac...
Asthma